75 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Looking For Generic Drug Stocks? Pick Up These Winners http://www.zacks.com/stock/news/223371/looking-for-generic-drug-stocks-pick-up-these-winners?cid=CS-ZC-FT-223371 Jul 13, 2016 - The short term earnings outlook for these stocks have been building momentum recently, so don't miss out!
Dr. Reddy's Laboratories Ltd's (RDY) CFO Saumen Chakraborty on Q1 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3379975-dr-reddys-laboratories-ltds-rdy-cfo-saumen-chakraborty-on-q1-2016-results-earnings-call-transcript?source=feed_tag_india Jul 31, 2015 - Dr. Reddy's Laboratories Ltd. (NYSE:RDY) Q1 2016 Earnings Conference Call July 30, 2015 9:00 AM ET Executives Kedar Upadhye – Head of Global Generics Finance & Investor Relations Saumen Chakrabort
AxoGen (AXGN) Shows Strength: Stock Moves 13.2% Higher http://www.zacks.com/stock/news/188100/shares-of-axogen-axgn-rose-over-13-in-the-last-session?cid=CS-ZC-FT-188100 Aug 28, 2015 - AxoGen (AXGN) was a big mover last session, with shares rising over 13% on the day.
AbbVie's Humira Gains FDA Approval for Label Expansion http://www.zacks.com/stock/news/189834/abbvies-humira-gains-fda-approval-for-label-expansion?cid=CS-ZC-FT-189834 Sep 11, 2015 - AbbVie (ABBV) gained ninth FDA approval for Humira for the treatment of patients suffering from moderate-to-severe hidradenitis suppurativa.
AbbVie Seeks FDA Approval for Imbruvica's Label Expansion http://www.zacks.com/stock/news/190147/abbvie-seeks-fda-approval-for-imbruvicas-label-expansion?cid=CS-ZC-FT-190147 Sep 15, 2015 - AbbVie (ABBV) is looking to get Imbruvica approved in the U.S. for the front-line treatment of patients suffering from chronic lymphocytic leukemia.
BioMarin-Dr. Reddy's Agree to Settle Kuvan Patent Litigation http://www.zacks.com/stock/news/190775/biomarin-dr-reddys-agree-to-settle-kuvan-patent-litigation?cid=CS-ZC-FT-190775 Sep 21, 2015 - BioMarin (BMRN) announced that it has entered into a settlement agreement with Dr. Reddy's (RDY) to resolve the patent litigation related to Kuvan.
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain http://www.zacks.com/stock/news/223394/teva-teva-provides-2016-2019-outlook-shares-gain?cid=CS-ZC-FT-223394 Jul 14, 2016 - Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
Dr. Reddy's Laboratories' (RDY) Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3991851-dr-reddys-laboratories-rdy-q2-2016-results-earnings-call-transcript?source=feed_tag_india Jul 27, 2016 - Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q2 2016 Earnings Conference Call July 26, 2016 09:00 ET Executives Kedar Upadhye - Investor Relations Saumen Chakraborty - Chief Financial Officer Abhijit M
New Strong Sell Stocks for April 20th http://www.zacks.com/stock/news/256987/new-strong-sell-stocks-for-april-20th?cid=CS-ZC--256987 Apr 20, 2017 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4 http://www.zacks.com/stock/news/260595/dr-reddys-rdy-earnings-revenues-decline-y-y-in-q4?cid=CS-ZC-FT-260595 May 15, 2017 - Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.

Pages: 123456...8

Page 1>